article thumbnail

IMV: Nuclear medicine procedure volumes decrease

AuntMinnie

Total nuclear medicine patient study volumes decreased by 5.7% decrease in hospital-based studies and a 2.5% decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. and non-hospital procedures increasing by 1.2%. Of these, 5.8

article thumbnail

Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

Imaging Technology

Urbain, MD, PhD, FASNC , professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo , Buffalo, New York. and ‘How can we ensure diversity in all parts of the nuclear medicine family?’

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

HPI: Almost a third of image interpretation done by nonradiologists

AuntMinnie

of all imaging studies for Medicare fee-for-service beneficiaries in 2022, but that the remaining 27.9% The team conducted a study that included data from 123 million 2022 Medicare Part B imaging claims. for nuclear medicine 33.9% Nuclear medicine 11.8% Nuclear medicine 11.8% Of these, 88.5

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens is a Senior Market Research Program Manager at IMV Medical Information Division, part of Science and Medicine Group.

PET Scan 115
article thumbnail

FAPI-PET bests FDG-PET in detecting gastrointestinal cancer

AuntMinnie

Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

Thomas Hope, MD, a radiologist and nuclear medicine physician at the University of California, San Francisco (UCSF), said that approval of lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand has driven a marked interest and excitement about theranostics and radioligand therapies (RLT). Hope added. Hope added.

article thumbnail

The rise of theranostics: Part 1 -- Gaining momentum

AuntMinnie

Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. The nuclear radiologist, nuclear medicine technologist, and radiation safety team are all present to administer an infusion.